期刊文献+

耐亚胺培南铜绿假单胞菌膜孔蛋白OprD2基因突变与耐药分析

Mutations in the membrane pore-protein OprD2 gene and drug resistance analysis of imipenem resistant Pseudomonas aeruginosa
下载PDF
导出
摘要 目的分析耐亚胺培南铜绿假单胞菌膜孔蛋白OprD2基因突变与耐药情况。方法收集2019年1月至2021年12月南京市高淳人民医院临床标本中的亚胺培南耐药与敏感的铜绿假单胞菌株共90株,均进行细菌鉴定、药敏试验和实时荧光定量PCR检测,对膜孔蛋白OprD2表达量降低的耐亚胺培南铜绿假单胞菌株进行基因序列检测。分析细菌鉴定、药敏试验结果和标本来源情况,比较耐药组与敏感组OprD2的mRNA表达量,分析耐亚胺培南铜绿假单胞菌的抗菌药敏感性结果、OprD2基因突变类型。结果90株亚胺培南耐药与敏感铜绿假单胞菌中,仪器法最低抑菌浓度≥8μg/ml、纸片抑菌圈≤15mm共45株,纳为耐药组;仪器法最低抑菌浓度≤2μg/ml、纸片抑菌圈≥19mm共45株,纳入敏感组。90株亚胺培南耐药与敏感铜绿假单胞菌主要分布于呼吸内科(40.00%)、神经内科(33.33%),标本类型主要为痰(41.11%)。耐药组铜绿假单胞菌OprD2基因的mRNA表达量为0.32(0.03,1.23),低于敏感组的0.70(0.06,2.68),差异有统计学意义(P<0.05)。耐亚胺培南铜绿假单胞菌株均对亚胺培南、哌拉西林完全耐药,对头孢他啶、哌拉西林/他唑巴坦、美罗培南耐药率较低,对阿米卡星、庆大霉素完全敏感,而无耐药性。45株耐亚胺培南株菌中,检出OprD2基因突变或缺失40株,占比88.89%;其中终止密码提前7株、非中断突变及PCR扩增阴性均5株、移码突变13株。结论OprD2基因突变或缺失,会导致膜孔蛋白OprD2表达量明显下降,促使铜绿假单胞菌对亚胺培南产生耐药。 Objective To analyze the mutation in the membrane pore-protein OprD2 gene and drug resistance of imipenem resistant Pseudomo-nas aeruginosa.Methods A total of 90 imipenem resistant and sensitive Pseudomonas aeruginosa strains were collected from clinical samples of Nanjing Gaochun People's Hospital from January 2019 to December 2021,bacterial identification,drug sensitivity test,real-time fluorescence quan-titative PCR detection were performed for all strains,gene sequence detection was performed for the imipenem resistant pseudomonas aeruginosa strains with reduced expression of membrane porin OprD2.Bacterial identification,drug susceptibility test results and specimen sources were ana-lyzed,the mRNA expression of OprD2 was compared between the drug resistance group and the sensitive group,the antimicrobial susceptibility re-sults of imipenem-resistant Pseudomonas aeruginosa and the type of OprD2 gene mutation were analyzed.Results Among the 90 imipenem resis-tant and sensitive Pseudomonas aeruginosa strains,45 strains with minimum inhibitory concentration≥8μg/ml by instrument method and disk inhibi-tion zone≤15 mm by paper method were included in the drug resistance group;45 strains with minimum inhibition concentration≤2μg/ml by instru-ment method and disk inhibition zone≥19 mm by paper method were included in the sensitive group.The 90 strains of imipenem resistant and sensi-tive Pseudomonas aeruginosa were mainly distributed in respiratory department(40.00%)and neurology department(33.33%),and the main speci-men type was sputum(41.11%).The mRNA expression levels of OprD2 gene of Pseudomonas aeruginosa in the drug resistant group was 0.32(0.03,1.23),which was lower than 0.70(0.06,2.68)in the sensitive group,and the difference was statistically significant(P<0.05).Imipenem resistant Pseudomonas aeruginosa strains are completely resistant to imipenem and piperacillin,and had low resistance rates to ceftazidime,piperacillin/tazo-bactam,and meropenem,and were completely sensitive to amikacin and gentamicin,but had no resistance.Among 45 imipenem-resistant strains,40 strains with OprD2 gene mutation or deletion were detected,accounting for 88.89%;among them,there were 7 stopped code advanced,5 non-inter-rupted mutations and negative PCR amplification,and 13 frameshift mutations.Conclusion The mutation and deletion of OprD2 gene can signifi-cantly decrease the expression of membrane pore protein OprD2,and promote the resistance of Pseudomonas aeruginosa to imipenem.
作者 万会林 诸君 孔燕 WAN Huilin;ZHU Jun;KONG Yan(Department of Clinical Laboratory,Nanjing Gaochun People's Hospital,Nanjing,Jiangsu,211300,China)
出处 《当代医学》 2023年第34期64-67,共4页 Contemporary Medicine
关键词 亚胺培南 铜绿假单胞菌 OprD2基因突变 耐药机制 Imipenem Pseudomonas aeruginosa OprD2 gene mutation Resistance mechanisms
  • 相关文献

参考文献14

二级参考文献126

  • 1Jevitt LA,Patel JB,Tenover FC,et al.Evaluation of FDA-Approved Disk Dffusion Breackpoint for Daptomycin.2004.ICAAC abstract 48.
  • 2National Committee of Clinical Laboratory Standards. 2005.24. Performance standards for antimicrobial susceptibility testing; fiveteenth informational supplement. Nccls document M100-S15. Wayne. Pennsylvania: NCCLS, 2005.1-159.
  • 3National Committee of Clinical Laboratory Standards. 2003. Performance standards for antimicrobial disk susceptibility testing; Approved standard-eighth edition. NCCLS document, M2-A8. Wayne. Pennsylvania: NCCLS, 2003.1-70.
  • 4National Committee of Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically. M7-A6. Wayne. Pennsylvania: NCCLS, 2003.1-50.
  • 5Schwaber MJ, Raney PM, Rasheed JK, et al.Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and Non-Klebsiella spp. of Enterobacteriaceae.J Clin Microbiol,2004 ,42:294-298.
  • 6Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.J Clin Microbiol, 2001 ,39:183-190.
  • 7.[EB/OL].www.cdc.gov/ncidod/hip/vanco/vanco.htm,.
  • 8Rezai K,Quinn JP,Hayes R,et al.Emergence Daptomycin(D)Resistance and Treatment Failure 2 cases of S.aureus Osteomyeliyis.2004.ICAAC abstract97△.
  • 9颜英俊,喻华,周忠华,鲁芳,刘华,乔宁,黄文芳.亚胺培南耐药的铜绿假单胞菌中oprD基因突变研究[J].中华检验医学杂志,2009,32(4):451-454. 被引量:11
  • 10裴保香,秦攀,罗燕萍.铜绿假单胞菌耐药性与抗菌药物用量变化的相关性分析[J].中华医院感染学杂志,2010,20(7):993-995. 被引量:18

共引文献112

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部